The Role of Biomarkers to Evaluate Cardiotoxicity

Opinion statement Moderate-level evidence suggests that cardiac troponin and natriuretic peptides are useful for risk stratification and early identification of anthracycline cardiotoxicity; however, many of these studies used older chemotherapy regimens, and thus, the applicability to current anthr...

Full description

Saved in:
Bibliographic Details
Published in:Current treatment options in oncology 2020-08, Vol.21 (10), p.79, Article 79
Main Author: Upshaw, Jenica N.
Format: Article
Language:English
Subjects:
Anthracycline
Biomarkers
Calcium-binding protein
Cardio-oncology (MG Fradley
Cardiotoxicity
Chemotherapy
Clinical trials
ErbB-2 protein
Heart
Heart failure
Medicine
Medicine & Public Health
Oncology
Peptides
Risk factors
Section Editor
Thorax
Topical Collection on Cardio-oncology
Troponin
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Opinion statement Moderate-level evidence suggests that cardiac troponin and natriuretic peptides are useful for risk stratification and early identification of anthracycline cardiotoxicity; however, many of these studies used older chemotherapy regimens, and thus, the applicability to current anthracycline treatment regimens is uncertain. Further research is needed to determine optimal timing and thresholds for troponin and natriuretic peptides in anthracycline-treated patients and evaluate these and other promising biomarkers for anti-HER2 therapies, thoracic radiation, anti-VEGF therapy, and fluoropyrimidine therapy–related cardiotoxicity. Risk tools that combine cardiac risk factors, cancer treatment variables, biomarkers, and imaging parameters are most likely to accurately identify individuals at highest risk for cancer therapy cardiotoxicity. Clinical trials focusing cardioprotective strategies on high-risk individuals are more likely to result in clinically significant results compared with primary prevention cardioprotective approaches.
ISSN:1527-2729
1534-6277
1534-5277
DOI:10.1007/s11864-020-00777-1